Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2015

View Archived Issues

Galectin Therapeutics finds no drug-drug interaction between GR-MD-02 and midazolam

Merck & Co. funds Canadian research institute collaborations

Mochida and Merck & Co. terminate diabetes collaboration

Epirus licenses Latin American rights to infliximab biosimilar to mAbxience

Lilly and Sanford-Burnham collaborate on immunological therapies

DoD contract provides funding for AcelRx's development of ARX-04

Eisai offers overview of fourth quarter of fiscal 2014

RadioMedix and AREVA Med to codevelop treatment for neuroendocrine tumors

Bristol-Myers Squibb divulges inhibitors of HIV replication

ARHGEF15 shows potential as a prognosic biomarker for PDAC

Serum FGF-21 as a highly sensitive biomarker for early diagnosis of breast cancer

HedgePath receives investment from Mayne Pharma and plans SUBA-Itraconazole trial

Sorrento Therapeutics focuses on immuno-oncology and resiniferatoxin for cancer pain

ADDF grant supports Oryzon's development of ORY-2001 for Alzheimer's disease

Novel approach to identify aggressive susceptibility genes in prostate cancer

Oncolytics Biotech's Reolysin cleared to start pediatric phase I trial in brain tumors

Tacrolimus shows efficacy as the first medical therapy for cherubism

Debiopharm reports results of phase III trial of triptorelin in central precocious puberty

STAT-3 inhibitors: a promising therapy to treat necrotizing enterocolitis

Janssen and Achillion establish global HCV collaboration

French investigators patent chimeric proteins for amyloidosis

Medivir discloses RSV replication inhibitors

Bayer Schering Pharma presents BUB1 inhibitors

Sunshine Lake Pharma develops FFAR1 agonists

Prima BioMed releases final data from phase II ovarian cancer study of CVac

Full results of DELOS trial of idebenone in DMD reported

Invega Trinza approved in U.S. for 3-monthly treatment of schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...